Quest Diagnostics Incorporated
As of Oct 22, 2026, Quest Diagnostics is in Stage 2, the uptrend phase, now in week 17 (since Jun 25, 2026). It closed at $243.28, 1.3% below its 52-week high and above its 200-day average, which is rising.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is DGX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DGX among Diagnostics & Research13th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …13 | DGX | Stage 2 · wk 17 | 79 | +4.8% |
Quest Diagnostics: quick answers
What stage is Quest Diagnostics in?
As of Oct 22, 2026, Quest Diagnostics (DGX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 25, 2026 and is in week 17. What the four stages mean
Is Quest Diagnostics in an uptrend?
Yes. Quest Diagnostics is in a Stage 2 uptrend. It trades 16.6% above its 200-day average, which is rising.
How far is Quest Diagnostics from its 52-week high?
Quest Diagnostics closed at $243.28 on Oct 22, 2026, 1.3% below its 52-week high of $246.53. Its 52-week low is $170.62.
How has Quest Diagnostics performed over the past year?
As of Oct 22, 2026, Quest Diagnostics is up 34.0% over the past year and up 42.3% so far in 2026.
Which sector and industry is Quest Diagnostics in?
Quest Diagnostics is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.